Amorphous Polypeptide Film Stabilization via Amphiphilic Surfactants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmaceutically active polypeptides face stability issues at ambient temperatures, limiting their use due to degradation, which requires refrigeration and restricts their potential as disease therapy candidates.
Innovation Solution
A composition comprising an amorphous, substantially solid film with a biologically active polypeptide, a sugar, and an amphipathic surfactant, specifically poly(maleic anhydride-alt-1 octadecene) substituted with 3-(dimethylamino) propylamine, which maintains stability and activity even at room temperature for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If polypeptides are stored at ambient temperature, then storage and transport convenience is improved, but polypeptide stability deteriorates due to degradation
Solution Approach 1:
The patent changes the physical and chemical parameters of the polypeptide formulation by incorporating specific excipients (surfactants, sugars, amino acids) and adjusting pH and ionic strength to create a stable formulation that maintains polypeptide integrity at ambient temperatures without refrigeration
Solution Approach 2:
The invention creates a composite formulation system combining polypeptides with multiple stabilizing excipients including surfactants (e.g., polysorbates, lecithin), sugars (e.g., sucrose, trehalose), and amino acids, where each component contributes to maintaining polypeptide stability through different mechanisms such as preventing aggregation, adsorption, and chemical degradation
2Stability of the object's composition
If refrigeration is used to maintain polypeptide stability, then polypeptide stability is improved, but device complexity and storage requirements worsen due to cold chain requirements
Solution Approach 1:
The formulation parameters are optimized to shift the stability profile of polypeptides from temperature-sensitive to temperature-resistant, allowing storage at 2-8°C or even at room temperature up to 25°C for extended periods, thereby eliminating or reducing cold chain requirements
Solution Approach 2:
The patent enables the use of simple, inexpensive storage containers without specialized refrigeration equipment, making the distribution system more accessible and reducing infrastructure requirements for polypeptide storage and transport
3Stability of the object's composition
If polypeptides are formulated with stabilizing excipients, then polypeptide stability is improved, but formulation complexity worsens
Solution Approach 1:
The patent identifies and utilizes excipients that perform multiple functions simultaneously: surfactants prevent both aggregation and adsorption to surfaces, sugars provide both steric stabilization and water activity control, and amino acids can prevent both chemical degradation and physical aggregation, thereby simplifying the overall formulation strategy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition retains significant biological activity of the polypeptide, allowing for storage and transport without a cold chain, and can be rapidly dissolved for use as therapeutics or diagnostics, overcoming the stability limitations of previous formulations.
Implementation Method 1
an amphipathic surfactant, specifically poly(maleic anhydride-alt-1 octadecene), wherein the poly(maleic anhydride-alt-1 octadecene) is substituted with 3-(dimethylamino) propylamine
Implementation Method 2
the amphipathic surfactant comprises poly(maleic anhydride-alt-1 octadecene), wherein the poly(maleic anhydride-alt-1 octadecene) is substituted with 3-(dimethylamino) propylamine
Implementation Method 3
an amorphous, substantially solid film having an average thickness of 0.005 to 5 mm
Data Source
Figure 1
Figure 2A~2B
Figure 3~4
AI summary
Soluble film compositions comprising biologically active polypeptides are provided, which stabilize the polypeptides. Methods for administering, formulating and stabilizing polypeptides are also provided.